Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Prevalence of EGFR Mutations in Participants With NSCLC

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2016-03-01

Last Posted Date: 2016-07-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 69

Registration Number: NCT02695849

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2016-02-29

Last Posted Date: 2017-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT02694718

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2016-02-29

Last Posted Date: 2017-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT02694536

A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Cyclophosphamide
Other: Placebo Cyclophosphamide
Other: Placebo Methotrexate
Other: Placebo Rituximab
Drug: Rituximab

First Posted Date: 2016-02-26

Last Posted Date: 2016-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 161

Registration Number: NCT02693210

Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

Phase 3

Completed

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporine
Drug: Daclizumab
Drug: Mycophenoate Mofetil
Drug: Prednisolone
Drug: Sirolimus

First Posted Date: 2016-02-19

Last Posted Date: 2016-02-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 237

Registration Number: NCT02686619

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Device: AI-1000 G2
Drug: Tocilizumab

First Posted Date: 2016-02-15

Last Posted Date: 2019-04-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT02682823

Locations: 🇺🇸
Metroplex Clinical Research, Dallas, Texas, United States
🇺🇸
Pacific Arthritis Ctr Med Grp, Santa Maria, California, United States
🇺🇸
Valerius Medical Group & Research Ctr of Greater Long Beach, Los Alamitos, California, United States

and more 5 locations

A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease

Phase 1

Completed

Conditions: Celiac Disease

Interventions: Drug: Placebo
Drug: RO5459072

First Posted Date: 2016-02-10

Last Posted Date: 2017-08-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 19

Registration Number: NCT02679014

Locations: 🇬🇧
Hammersmith Medicines Research Ltd., London, United Kingdom

A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: TNF inhibitor/TCZ

First Posted Date: 2016-02-10

Last Posted Date: 2018-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 200

Registration Number: NCT02679001

Locations: 🇸🇪
Örebro Uni Hospital; Rheumatology, Oerebro, Sweden
🇸🇪
Mälarsjukhuset; Reumatologkliniken, Eskilstuna, Sweden
🇸🇪
Arvika Sjukhus; Reumatologimottagningen - Medicinmottagningen, Arvika, Sweden

and more 8 locations

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Device: AI-1000 G2
Device: PFS-NSD
Drug: Tocilizumab

First Posted Date: 2016-02-10

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 189

Registration Number: NCT02678988

Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)

Completed

Conditions: Carcinoma, Basal Cell

Interventions: Drug: Vismodegib

First Posted Date: 2016-02-04

Last Posted Date: 2019-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 67

Registration Number: NCT02674009

Locations: 🇩🇪
Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy